APIM Therapeutics AS

close up picture of an DNA string
Visit company website

APIM Therapeutics AS is a clinical-stage biotech company developing first-in-class peptide drugs against multiple cancers.

The drug targets the PCNA/APIM stress switch, a novel intervention point controlling cellular stress responses (e.g. DNA Damage Response). The approach is based on research from the University of Science and Technology, NTNU, Trondheim, and allows for the potentiation of the action of >25 clinical drugs across multiple cancer indications. ATX-101, the company’s current lead, has shown strong preclinical proof-of-efficacy in preclinical models of bladder, breast, multiple myeloma, AML and prostate cancer in combination with several anti-cancer drugs.

Latest news about APIM Therapeutics AS

  • Tue May 18 2021

    APIM Therapeutics completes private placement and enters phase-2

    APIM Therapeutics today announces the completion of a private placement directed towards existing an

    Read full article
  • Tue May 11 2021

    APIM Therapeutics announces IND for ATX-101 in Ovarian Cancer

    APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Inv

    Read full article